Efavirenz-induced neurological symptoms in rare homozygote CYP2B62/2 (C64T)

被引：8

作者：

Usami, Osamu

Ashino, Yugo

Komaki, Yuichi

Tomaki, Masafurni

Irokawa, Toshiya

Tamada, Tsutornu

Hayashida, Tsunefusa

Teruya, Katsuji

Hattori, Toshio

机构：

[1] Tohoku Univ, Div Infect & Resp Dis, Aoba Ku, Sendai, Miyagi 980, Japan

[2] Int Med Ctr Japan, AIDS Clin Ctr, Tokyo, Japan

来源：

INTERNATIONAL JOURNAL OF STD & AIDS | 2007年 / 18卷 / 08期

关键词：

polymorphism; SNP; HIV; HAART; Japan; REVERSE-TRANSCRIPTASE INHIBITOR; CYTOCHROME P4502B6 GENE; ALLELE FREQUENCIES; CYP2B6; METABOLISM; PHARMACOKINETICS; VARIABILITY; THERAPY;

D O I：

10.1258/095646207781439810

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Some of the HIV-1 -infected patients who were given highly active anti-retroviral therapy (HAART) including efavirenz (EFV) presented adverse central nervous system (CNS) symptoms such as fatigue and insomnia. The incidence of adverse CNS symptoms is associated with hepatic cytochrome P450 isozymes (CYP2B6) polymorphisms. For example, CYP2B6 *6 (G516T and A785G) and *7 (G516T, A785G and C1459T) prolonged the EFV half-life despite discontinuation of EFV. CYP2B6 *2/*2 (C641) is extremely rare and there have been no data describing the EFV plasma concentrations in C64T homozygous patients, who developed adverse CNS symptoms. C64T homozygous possibly has some catalytic defects.

引用

收藏

页码：575 / 576

页数：2

相关论文

共 50 条

[41] Prenatal efavirenz exposure is independently associated with maternal, but not fetal CYP2B6 genotype [J].

Eniayewu, Oluwasegun ;

Akinloye, Abdulafeez ;

Shenkoya, Babajide ;

Azuka, Uche ;

Bolaji, Oluseye ;

Adejuyigbe, Ebunoluwa ;

Owen, Andrew ;

Olagunju, Adeniyi .

PHARMACOGENETICS AND GENOMICS, 2024, 34 (08) :253-260

[42] Functional characterization of 40 CYP2B6 allelic variants by assessing efavirenz 8-hydroxylation [J].

Watanabe, Takashi ;

Saito, Takahiro ;

Rico, Evelyn Marie Gutierrez ;

Hishinuma, Eiji ;

Kumondai, Masaki ;

Maekawa, Masamitsu ;

Oda, Akifumi ;

Saigusa, Daisuke ;

Saito, Sakae ;

Yasuda, Jun ;

Nagasaki, Masao ;

Minegishi, Naoko ;

Yamamoto, Masayuki ;

Yamaguchi, Hiroaki ;

Mano, Nariyasu ;

Hirasawa, Noriyasu ;

Hiratsuka, Masahiro .

BIOCHEMICAL PHARMACOLOGY, 2018, 156 :420-430

[43] Variants in the CYP2B6 3UTR Alter In Vitro and In Vivo CYP2B6 Activity: Potential Role of MicroRNAs [J].

Burgess, Kimberly S. ;

Ipe, Joseph ;

Swart, Marelize ;

Metzger, Ingrid F. ;

Lu, Jessica ;

Gufford, Brandon T. ;

Thong, Nancy ;

Desta, Zeruesenay ;

Gaedigk, Roger ;

Pearce, Robin E. ;

Gaedigk, Andrea ;

Liu, Yunlong ;

Skaar, Todd C. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2018, 104 (01) :130-138

[44] CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation [J].

Powers, V. ;

Ward, J. ;

Gompels, M. .

HIV MEDICINE, 2009, 10 (08) :520-523

[45] Effects of CYP3A5, CYP2C19, and CYP2B6 on the clinical efficacy and adverse outcomes of sibutramine therapy: A crucial role for the CYP2B6*6 allele [J].

Hwang, In Cheol ;

Park, Ji Young ;

Ahn, Hong Yup ;

Kim, Kyoung Kon ;

Suh, Heuy Sun ;

Ko, Ki Dong ;

Kim, Kyoung-Ah .

CLINICA CHIMICA ACTA, 2014, 428 :77-81

[46] Functional CYP2B6 variants and virologic response to an efavirenz-containing regimen in Port-au-Prince, Haiti [J].

Haas, David W. ;

Severe, Patrice ;

Juste, Marc Antoine Jean ;

Pape, Jean William ;

Fitzgerald, Daniel W. .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2014, 69 (08) :2187-2190

[47] CYP2B6*6, CYP2B6*18, Body weight and sex are predictors of efavirenz pharmacokinetics and treatment response: population pharmacokinetic modeling in an HIV/AIDS and TB cohort in Zimbabwe [J].

Milcah Dhoro ;

Simbarashe Zvada ;

Bernard Ngara ;

Charles Nhachi ;

Gerald Kadzirange ;

Prosper Chonzi ;

Collen Masimirembwa .

BMC Pharmacology and Toxicology, 16

[48] Genome-wide association study of plasma efavirenz pharmacokinetics in AIDS Clinical Trials Group protocols implicates several CYP2B6 variants [J].

Holzinger, Emily R. ;

Grady, Benjamin ;

Ritchie, Marylyn D. ;

Ribaudo, Heather J. ;

Acosta, Edward P. ;

Morse, Gene D. ;

Gulick, Roy M. ;

Robbins, Gregory K. ;

Clifford, David B. ;

Daar, Eric S. ;

McLaren, Paul ;

Haas, David W. .

PHARMACOGENETICS AND GENOMICS, 2012, 22 (12) :858-867

[49] Pharmacogenetic-Based Efavirenz Dose Modification: Suggestions for an African Population and the Different CYP2B6 Genotypes [J].

Mukonzo, Jackson K. ;

Owen, Joel S. ;

Ogwal-Okeng, Jasper ;

Kuteesa, Ronald B. ;

Nanzigu, Sarah ;

Sewankambo, Nelson ;

Thabane, Lehana ;

Gustafsson, Lars L. ;

Ross, Colin ;

Aklillu, Eleni .

PLOS ONE, 2014, 9 (01)

[50] The impact of CYP2B6 polymorphisms on the interactions of efavirenz with lumefantrine: Implications for paediatric antimalarial therapy [J].

Zakaria, Zaril ;

Badhan, Raj K. S. .

EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2018, 119 :90-101

← 1 2 3 4 5 →